Scientists see enormous potential in harnessing antibody drugs against an array of infectious-disease threats — if the costs come down. Multiple promising studies have identified antibody drugs ...

Two new drugs for Alzheimer’s have been rejected for use on the NHS. They slow progression of the disease, but they can have serious side-effects. – What are the medicines? Donanemab and lecanemab are ...

Scientists and doctors remain divided on the targeted antibody drugs that slow down the early stages of Alzheimer’s ...

On the heels of President Trump’s Monday announcement of an executive order to slash prescription drug prices in the U.S., the spotlight is on current costs and how much Americans could save.

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to justify their cost, the health spending watchdog has said.

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to justify their cost, the health spending watchdog has said. The National Institute ...

Lantern Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer Contacts Investor Relations [email protected] ...

It is the company's lead drug candidate in its pipeline of drugs. The novel ABS-101 antibody, ... comes with an enormous cost. A new drug takes, on average, 10 years to develop, ...

Lantern Pharma Inc., an artificial intelligence company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today ...

DALLAS, January 27, 2025--Lantern Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer ...